Skip to content

Effect of Oliceridine on Postoperative Recovery Quality in Elderly Patients Undergoing Radical Gastrectomy for Gastric Cancer: A Randomized Controlled Trial

Effect of Oliceridine on Postoperative Recovery Quality in Elderly Patients Undergoing Radical Gastrectomy for Gastric Cancer: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126624
Enrollment
Unknown
Registered
2026-06-12
Start date
2026-06-12
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative pain

Interventions

Oliceridine group:Oliceridine is utilized for analgesic induction, intraoperative analgesic transition, and postoperative analgesia.
Sufentanil group:Sufentanil is utilized for analgesic induction, intraoperative analgesic transition, and postoperative analgesia.

Sponsors

The first affiliated hostipal of nanchang university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged =65 years, regardless of gender. 2.American Society of Anesthesiologists (ASA) physical status classification II-III. 3.Scheduled for elective radical gastrectomy under general anesthesia. 4.Provision of written informed consent by the patient or their legal guardian.

Exclusion criteria

Exclusion criteria: 1.Preoperative severe cognitive impairment (e.g., MMSE score <9), rendering the patient unable to cooperate with pain scoring and questionnaire completion. 2.Severe hepatic or renal dysfunction (Child-Pugh class C or eGFR <30 mL/min/1.73m²); severe cardiac dysfunction. 3.Severe preoperative gastrointestinal motility disorders (e.g., intestinal obstruction, chronic constipation, inflammatory bowel disease); coagulopathy; respiratory insufficiency (preoperative SpO2 <90% or requiring long-term oxygen therapy); poorly controlled diabetes mellitus; or preexisting psychiatric disorders. 4.Known allergy or hypersensitivity to oxycodone, sufentanil, or their pharmaceutical excipients, constituting a contraindication. 5.Emergency surgery; history of alcoholism or substance abuse; anticipated inability to wean from mechanical ventilation postoperatively. 6.Anticipated intraoperative blood loss exceeding 1000 mL; or occurrence of major intraoperative complications. 7.Concurrent participation in another clinical trial that could potentially interfere with the results of this study.

Design outcomes

Primary

MeasureTime frame
Postoperative recovery quality;

Secondary

MeasureTime frame
Recovery time after surgery;Pain Scores;Severity of Postoperative Nausea and Vomiting;

Countries

China

Contacts

Public ContactSun wenjie

The first affiliated hostipal of nanchang university

swj6740@163.com+86 157 9769 2874

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026